| Product Name | Hyp ELISA kit (General species) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Hydroxyproline (Hyp). No significant cross-reactivity or interference between Hydroxyproline (Hyp) and analogues was observed. |
| Synonyms | (2S,4R)-4-Hydroxyproline; L-Hydroxyproline(C5H9O3N) |
| Method | Competitive |
| Detection Range | 61.7-5,000ng/mL |
| Sensitivity | 28.5ng/mL |
| Target | Hyp |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Hydroxyproline (Hyp). No significant cross-reactivity or interference between Hydroxyproline (Hyp) and analogues was observed. |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix.Incubate 1 hour at 37℃; 3.Aspirate and wash 3 times; 4.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 5.Aspirate and wash 5 times; 6.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 7.Add 50uL Stop Solution.Read at 450 nm immediately. |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Spleen-Derived Interleukin-10 Downregulates the Severity of High-Fat Diet-Induced Non-Alcoholic Fatty Pancreas Disease;Prediction of fibrosis in hepatitis C patients: assessment using hydroxyproline and oxidative stress biomarkers;Royal jelly affects collagen crosslinking in bone of ovariectomized rats;Tanshinone IIA ameliorates bleomycin-induced pulmonary fibrosis and inhibits transforming growth factor-beta-β–dependent epithelial to mesenchymal transition;Theophylline, an old drug with multi-faceted effects: Its potential benefits in immunological liver injury in rats;Effects of 4% Icodextrin on Experimental Spinal Epidural Fibrosis;Celecoxib attenuates depressive-like behavior associated with immunological liver injury inC57BL/6 mice through TNF-α and NF-κb dependent mechanisms.;Sustained-released mixture of vascular endothelial growth factor 165 and fibrin glue strengthens healing of ileal anastomoses in a rabbit model with …;Effects of panax notoginseng saponin on the pathological ultrastructure and serum IL‐6 and IL‐8 in pulmonary fibrosis in rabbits;Renin–angiotensin system inhibition ameliorates CCl-induced liver fibrosis in mice through the inactivation of nuclear transcription factor kappa B;Pirfenidone suppresses bleomycin‑induced pulmonary fibrosis and periostin expression in rats;Therapeutic effect of hepatocyte growth factor-overexpressing bone marrow-derived mesenchymal stem cells on CCl 4-induced hepatocirrhosis.;The effects of platelet‐rich‐plasma gel application to the colonic anastomosis in hyperthermic intraperitoneal chemotherapy: An experimental rat model;Pantoea agglomerans chronic exposure induces epithelial-mesenchymal transition in human lung epithelial cells and mice lungs;Is platelet-rich plasma improves the anastomotic healing in hyperthermic intraperitoneal chemotherapy with oxaliplatin: an experimental rat study;Protective Effects of Contractubex® on Stricture Formation after Experimental Corrosive Esophageal Burns in Rats;Effect of Oral Channa striatus in Laparotomy Wound Healing of Malnourished Rats.;Handgrip Strength and Vitamin D as Predictors of Liver Fibrosis and Malnutrition in Chronic Hepatitis C Patients;Beneficial impact of cathelicidin on hypersensitivity pneumonitis treatment¡ªIn vivo studies;Curdione and Schisandrin C Synergistically Reverse Hepatic Fibrosis via Modulating the TGF-β Pathway and Inhibiting Oxidative Stress; |
| Supplier | Cloud Clone |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.